Minutes - Medication WG 2022-02-15
From Health Level 7 Belgium Wiki
Attendees
- An Crepel, digile
- Annemieke Vergauwe
- Bart Decuypere
- Jan Lenie
- Jean-Michel Polfliet
- Jens Penny
- José Costa Teixeira
- Karlien Erauw
- Kris Deceunynck
- Pablo Christiaens
- Thomas Van Langendonck
- Tom Henkens
Excused/Not present
- Anne Nerenhausen
- Bruno Casneuf
- Dieter Sauvillers
- Elhassan Baazizi
- Hanne Vuegen
- Jean-Louis Maggetto
- Jeroen De Wilde
- Katrien Thorré
- Lars Vanreppelen
- Marc Buckens
- Nick Hermans
- Nils Devos
- Richard Francken
- Thomas Van Langendonck
- Tom De Backer
- Walter Bollaert
- Will van Norel
Agenda
- presentation and discussion on drug databases
Minutes
- An from Digile has worked on the SAM database and has plenty of drug data expertise
- BCFI, the green booklet used by pharmacists & doctors
- BCFI was structured in a Repertorium drug tables
- SAM is a consortium: APB, RIZIV, FOD VG, FAGG to put all drugs in one database
- VMP, VMP-groups are concepts were implemented through guidance from BCFI
- public SAM viewer was developed by Digile, visualisation in an intuitive manner that has the full SAMv2 content (2 updates a day - not realtime), is public
- feedback option is available as there are still some data quality issues & inconsistencies with SAM
- difficult follow-up on raised issues
- overview of VOs-groups to improve easier access to these data that was not open to the public before
- ISO IDMP gap analysis on SAM V2 has been done
- ISO IDMP does not present a fixed vocabulary
- objective is to map SAMv2 to ISO IDMP database, works quite well although there are no identifiers in the 2 sytems
- attributes can be useful for the mapping
- How can we query with FHIR on SAMv2 ?
- f.e. if doctor wants to query on substance
- what are the logical models behind: see https://www.samportal.be/nl/sam/documentation PIM logical model
- Concept of VMP group: it is a clinical concept
- to add
- VMP is more a regulatory concept
- our WG goal: how to represent medication in a medication scheme - which recommendation is there ? current MS is focused on brand name, VOS-group of substance seems better from a clinical point of view of VMP-group as it includes the route of administration
- RIZIV wants a different view so both levels will have to be there (packages)
- VIDIS would like to have first artefacts of our WG
- medication treatment line are being worked on
- We have started working on a document listing different concepts that will be used in the medication scheme, how we consist
Action items for next meeting
- José to work on use cases and add medication view line in view and how it all works at operational level
- Jens to start writing up document
Next meeting March 1 at 11AM
